Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ENLV | US
0.07
8.37%
Healthcare
Biotechnology
30/06/2024
16/04/2026
0.89
0.82
0.90
0.80
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona Israel.
View LessStrength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
115.5%1 month
109.1%3 months
83.8%6 months
81.1%-
-
1.22
0.03
0.03
-1.49
-
-
-17.89M
19.02M
19.02M
-
-
-
-
-61.17
0.70
0.52
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.27
Range1M
0.58
Range3M
0.58
Rel. volume
1.69
Price X volume
1.60M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| iBio Inc | IBIO | Biotechnology | 2.11 | 19.28M | 0.48% | n/a | 20.92% |
| PLUR | PLUR | Biotechnology | 3.51 | 19.20M | 1.45% | n/a | 30845.83% |
| Can-Fite BioPharma Ltd | CANF | Biotechnology | 3.08 | 18.78M | -2.84% | n/a | 0.00% |
| DOMH | DOMH | Biotechnology | 2.94 | 18.45M | -3.92% | n/a | 7.66% |
| HCW Biologics Inc. Common Stock | HCWB | Biotechnology | 0.419 | 18.28M | 2.95% | n/a | -159.13% |
| ICU | ICU | Biotechnology | 4.16 | 17.44M | 7.77% | n/a | -45.50% |
| Inhibikase Therapeutics Inc. | IKT | Biotechnology | 1.7 | 16.96M | -5.03% | n/a | 3.49% |
| Edesa Biotech Inc | EDSA | Biotechnology | 5.14 | 16.69M | -4.10% | n/a | 1.35% |
| VistaGen Therapeutics Inc | VTGN | Biotechnology | 0.6031 | 16.32M | -1.36% | n/a | 1.90% |
| Cingulate Inc. Common Stock | CING | Biotechnology | 5.26 | 16.01M | 1.15% | n/a | 10.72% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.612 | 11.83M | -2.84% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.74 | 10.81M | 6.52% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.335 | 3.41M | -2.06% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2167 | 2.06M | -6.19% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.44 | 793.44K | -17.24% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.005 | 461.07K | 0.00% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.49 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.22 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 83.83 | - | Par |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.03 | 0.25 | Cheaper |
| Market Cap | 19.02M | - | Emerging |